

Supplementary Information

Image-Guided Nanodelivery of Pt(IV) Prodrugs to GRP-Receptor Positive Tumors

Francisco Silva^{1,*}, Carolina Mendes¹, Alice D’Onofrio¹, Maria Paula Cabral Campello^{1,2}, Fernanda Marques^{1,2}, Teresa Pinheiro^{2,3}, Kyle Gonçalves¹, Sérgio Figueiredo^{4,5}, Lurdes Gano^{1,2}, Mauro Ravera⁶, António Paulo^{1,2*}

Index

Figure S 1. Schematic synthesis of the pegylated thioctic acid precursors.	1
Figure S 2. ESI-MS spectra.	1
Figure S 3. ^1H , ^{13}C and ^{195}Pt NMR spectra in DMSO-d ₆ of AuNP-BBN-Pt1 .	2
Figure S 4. ^1H , ^{13}C and ^{195}Pt NMR spectra in DMSO-d ₆ of AuNP-BBN-Pt2 .	3
Figure S 5. TEM imaging of the Pt(IV) prodrug-containing AuNPs.	4
Figure S 6. iTLC radiochromatograms of ^{67}Ga -AuNP-BBN-Pt2 and ^{67}Ga -AuNP-BBN-Pt3.	4
Figure S 7. Binding Affinity curves and IC ₅₀ values of the Pt(IV) prodrug-containing AuNPs.	5
Table S 1. Biodistribution study of ^{67}Ga -AuNP-BBN-Pt1 in PC3 xenograft model, upon bolus intratumoral administration performed at 1, 24 and 72 h post-administration.	6




Figure S 1. Schematic synthesis of the pegylated thioctic acid precursors.







Figure S 2. A. TA-Pt1: $m/z [C_{13}H_{27}Cl_2N_3O_5PtS_2H]^+$: calc. = 636.0; found = 636.2, $[C_{13}H_{27}Cl_2N_3O_5PtS_2Na]^+$: calc. = 658.0; found = 658.2. **B.** TA-Pt2: $m/z [C_{20}H_{40}PtCl_2N_4O_8S_2H]^+$ calc. = 795.1; found = 795.3 $[C_{20}H_{40}PtCl_2N_4O_8S_2Na]^+$ calc. = 817.1; found = 817.2.




1H-NMR



13C-NMR



COSY



HSQC







Figure S 3. Characterization of the thioctic acid-containing Pt(IV) prodrug **TA-Pt1** by multinuclear ^1H , ^{13}C and ^{195}Pt NMR analysis in DMSO-d₆.




1H-NMR



13C-NMR



COSY



HSQC




Figure S 4. Characterization of the thiocarbamate-containing Pt(IV) prodrug **TA-Pt2** by multinuclear ^1H , ^{13}C and ^{195}Pt NMR analysis in DMSO- d_6 .




Figure S 5. TEM imaging of the Pt(IV) prodrug-containing AuNPs.





Figure S 6. iTLC radiochromatograms of ^{67}Ga -AuNP-BBN-Pt2 and ^{67}Ga -AuNP-BBN-Pt3.



Compound	IC_{50}
AuNP-BBN-Pt1	$0.055 \pm 0.005 \mu\text{g/mL}$
AuNP-BBN-Pt2	$0.160 \pm 0.022 \mu\text{g/mL}$
AuNP-BBN-Pt3	$0.096 \pm 0.019 \mu\text{g/mL}$

Figure S 7. Binding Affinity curves and IC_{50} values of the Pt(IV) prodrug-containing AuNPs obtained by competitive binding assay using PC3 cells and [^{125}I -Tyr4]BBN as the GRPR-specific radioligand.

Table S 1. Biodistribution data of **^{67}Ga -AuNP-BBN-Pt1** in PC3 xenograft model, upon bolus intratumoral administration, performed at 1, 24 and 72 h post-administration.

Organ	% Injected Dose/organ		
	1 h	24 h	72 h
Blood	3.4 ± 0.7	1.29 ± 0.02	0.43 ± 0.08
Liver	0.7 ± 0.3	7.0 ± 0.9	4.7 ± 0.6
Intestine	0.9 ± 0.4	3.1 ± 0.2	2.3 ± 0.2
Spleen	0.04 ± 0.01	0.43 ± 0.01	0.17 ± 0.02
Heart	0.14 ± 0.01	0.05 ± 0.01	0.06 ± 0.01
Lung	0.16 ± 0.07	1.1 ± 0.2	0.20 ± 0.07
Kidney	0.3 ± 0.1	1.1 ± 0.1	1.3 ± 0.1
Muscle	2.3 ± 1.0	2.2 ± 0.1	2.5 ± 0.3
Bone	0.9 ± 0.3	4.6 ± 0.7	8.3 ± 1.0
Stomach	0.13 ± 0.05	0.28 ± 0.03	0.25 ± 0.02
Pancreas	0.08 ± 0.02	0.19 ± 0.06	0.22 ± 0.09
Brain	0.03 ± 0.01	0.05 ± 0.01	0.04 ± 0.01
Tumor	77.5 ± 0.7	34.3 ± 1.6	25.6 ± 10.6
Excretion	2.2 ± 1.0	34.5 ± 0.8	40.7 ± 2.6